US prevalence
100M US adults / 42.4%
Source: CDC NHANES 2017-2020
ConditionICD-10: E66.9
Obesity
Obesity is a chronic, progressive disease characterized by excess body fat that increases the risk of type 2 diabetes, heart disease, certain cancers, sleep apnea, and reduced quality of life. About 42% of US adults have obesity (BMI ≥ 30), making it one of the most common chronic conditions in the country.
Quick answer
UpdatedObesity is a chronic, complex disease characterized by excess adipose tissue that increases health risk. The AMA classified obesity as a disease in 2013. Approximately 100 million US adults (42.4%) have obesity (BMI ≥30); another 30%+ have overweight. GLP-1 receptor agonists (Wegovy 14.9% loss, Zepbound 22.5% loss) are the most effective non-surgical pharmacotherapy ever FDA-approved for chronic weight management.
- US prevalence: ~100 million adults (42.4%)
- CDC NHANES 2017-2020 data
- Annual US cost: ~$173 billion direct medical cost
- CDC 2019
- Wegovy efficacy: 14.9% body weight reduction
- STEP-1 trial, 68 weeks
- Zepbound efficacy: 22.5% body weight reduction
- SURMOUNT-1 trial, 72 weeks (highest in class)
- Cardiovascular benefit: 20% MACE reduction (Wegovy SELECT)
- Adults with obesity + established CVD
Annual US burden
$173 billion
Annual US direct medical cost
Source: CDC 2019
GLP-1 role
FDA-approved as standard pharmacotherapy alongside lifestyle modification. Wegovy and Zepbound carry indications for chronic weight management in adults with BMI ≥30 (or ≥27 with comorbidity).
Key takeaways
- • FDA labels require BMI 30+ or 27+ with comorbidity for approved weight-loss GLP-1s.
- • Mean weight loss: roughly 15% with semaglutide, roughly 21% with tirzepatide at one year.
- • Weight regain is common after stopping — most clinicians frame this as chronic therapy.
- • Off-label use of Ozempic/Mounjaro for weight loss is common but not FDA-sanctioned for that purpose.
- • Compounded versions are not FDA-approved as finished products.
Key facts
- •42.4% of US adults have obesity (CDC, 2024)
- •Mean weight loss in STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) Phase 3 trials: 15–22% over 68 weeks; individual results vary
- •Wegovy and Zepbound are FDA-approved for chronic weight management
- •Compounded semaglutide/tirzepatide offer lower-cost alternatives via telehealth
- •Obesity is recognized as a disease by the AMA (2013) and WHO
Why GLP-1 medications
GLP-1 receptor agonists slow gastric emptying, increase satiety, and reduce hunger signals — among the most effective non-surgical options in clinical trials. Phase 3 trials (STEP for semaglutide, SURMOUNT for tirzepatide) show sustained weight loss greater than prior anti-obesity medication classes studied to date.
GLP-1 drugs prescribed for Obesity
Each row links to its full review with current pricing, FDA status, and the best telehealth providers offering it. Discuss with your prescriber — these are treatment options, not personal recommendations.
- Wegovy$1349–$1500/mo
semaglutide
98/100 matchFDA-approved for chronic weight management + cardiovascular risk reduction
Compare providers - Zepbound$349–$1086/mo
tirzepatide
98/100 matchFDA-approved for chronic weight management + OSA in obesity
Compare providers - Saxenda$1100–$1500/mo
liraglutide
80/100 matchFDA-approved for chronic weight management — daily liraglutide
Compare providers - Compounded Semaglutide$99–$350/mo
semaglutide (compounded)
65/100 matchCompounded — lower cost but post-FDA-shortage regulatory uncertainty
Compare providers - Compounded Tirzepatide$149–$399/mo
tirzepatide (compounded)
65/100 matchCompounded — lower cost but post-FDA-shortage regulatory uncertainty
Compare providers
| Drug | Avg monthly cost | Indication match | Notes | Best providers |
|---|---|---|---|---|
| Wegovy semaglutide | $1349–$1500/mo | 98/100 | FDA-approved for chronic weight management + cardiovascular risk reduction | Compare |
| Zepbound tirzepatide | $349–$1086/mo | 98/100 | FDA-approved for chronic weight management + OSA in obesity | Compare |
| Saxenda liraglutide | $1100–$1500/mo | 80/100 | FDA-approved for chronic weight management — daily liraglutide | Compare |
| Compounded Semaglutide semaglutide (compounded) | $99–$350/mo | 65/100 | Compounded — lower cost but post-FDA-shortage regulatory uncertainty | Compare |
| Compounded Tirzepatide tirzepatide (compounded) | $149–$399/mo | 65/100 | Compounded — lower cost but post-FDA-shortage regulatory uncertainty | Compare |
Educational only. Discuss with your prescriber — these are treatment options, not personal recommendations. Indication-match scores reflect FDA approval status and published clinical evidence, not individual patient suitability.
Common symptoms
- BMI ≥ 30 (calculated as weight in kg ÷ height in m²)
- Excess body fat especially around the abdomen
- Difficulty with everyday physical activity
- Shortness of breath, fatigue, joint pain
- Sleep disturbance (snoring, sleep apnea)
- Skin issues in fat folds (intertrigo, acanthosis nigricans)
How obesity is diagnosed
BMI is the standard screening tool: BMI 25–29.9 = overweight, ≥30 = obesity (class I 30–34.9, class II 35–39.9, class III ≥40). BMI has limits (does not distinguish muscle from fat) so clinicians may add waist circumference, body composition, or metabolic labs. Class III obesity is sometimes called "severe" obesity and may qualify for bariatric surgery or higher-intensity treatment.
Treatment options
Lifestyle (first-line)
Diet (Mediterranean, low-carb), exercise (150+ min/wk moderate intensity), behavioral therapy. Average weight loss: 5–10% body weight over 12 months.
GLP-1 medications
Wegovy (semaglutide), Zepbound (tirzepatide) FDA-approved. Average loss: 15–22% body weight. Long-term use required to maintain loss.
Other anti-obesity meds
Contrave (naltrexone-bupropion), Qsymia (phentermine-topiramate), Saxenda (liraglutide), Plenity (hydrogel device). Less effective than GLP-1s, but cheaper or simpler.
Bariatric surgery
Gastric sleeve, gastric bypass. Best for BMI ≥40 or BMI ≥35 with comorbidity. Average loss: 25–35% body weight, durable long-term.
Compare telehealth providers for Obesity
SponsoredRanked by our editorial score. Visit a partner to check current pricing and eligibility — we never sell medications.
Advertising disclosure: we may earn a commission if you sign up through these links, at no extra cost to you — it never affects our rankings. How we make money
Lifestyle & self-care
- Build a sustainable calorie deficit (300–500 cal/day) — not aggressive restriction
- Prioritize protein (1.2–1.6 g per kg body weight) to preserve muscle during weight loss
- Strength training 2–3x/week prevents muscle loss that comes with rapid weight loss
- Track food intake for 2–4 weeks for awareness, then loosen
- Sleep 7+ hours — poor sleep increases hunger hormones (ghrelin) and reduces leptin
- Build social support — peers, accountability partners, behavioral coaches improve outcomes
When to see a doctor
Make an appointment if you have:
- →BMI ≥ 30 (or ≥ 27 with weight-related condition)
- →Difficulty losing weight despite consistent lifestyle effort
- →Weight gain affecting joints, breathing, or daily function
- →Family history of T2D, heart disease, or stroke
- →Considering anti-obesity medications or surgery
Medications for Obesity
Saxenda
liraglutide
GLP1Zoom score: 7.2/10
From $1100/mo
Wegovy
semaglutide
GLP1Zoom score: 8.9/10
From $1349/mo
Compounded Semaglutide
semaglutide (compounded)
GLP1Zoom score: 6.5/10
From $99/mo
Zepbound
tirzepatide
GLP1Zoom score: 9.3/10
From $349/mo
Compounded Tirzepatide
tirzepatide (compounded)
GLP1Zoom score: 6.5/10
From $149/mo
Not sure which medication is right for you?
Take our 60-second quiz and get a personalized match.
Take the quizObesity& GLP-1 — frequently asked questions
Can GLP-1 medications treat Obesity?
GLP-1 receptor agonists slow gastric emptying, increase satiety, and reduce hunger signals — among the most effective non-surgical options in clinical trials. Phase 3 trials (STEP for semaglutide, SURMOUNT for tirzepatide) show sustained weight loss greater than prior anti-obesity medication classes studied to date.
Which GLP-1 medications are used for Obesity?
GLP-1 options associated with Obesity include Wegovy, Zepbound, Saxenda, Contrave, Qsymia. FDA approval is indication-specific — confirm the right medication with your prescriber.
Is GLP-1 therapy FDA-approved for Obesity?
FDA approval is indication-specific. Some GLP-1 medications are FDA-approved for Obesity or a closely related indication, while others are prescribed off-label under clinical judgment. Always verify the approved indication for your specific medication.
Sources
- CDC Adult Obesity Facts
- STEP Trial — semaglutide for weight loss
- SURMOUNT-1 — tirzepatide for weight loss
- AMA Resolution 420 (2013): Obesity as a disease
Educational content; not a substitute for professional medical advice. Always consult a licensed clinician.
Diagnostic algorithm
How Obesity is diagnosed
Who diagnoses: Primary care provider, obesity medicine specialist. This is the standard clinical algorithm — not self-diagnosis guidance. Always work with your clinician for actual diagnosis.
- 1
BMI calculation
Clinic-measured height + weight
Threshold: ≥30 = obesity class I; ≥35 = class II; ≥40 = class III
- 2
Waist circumference
Central adiposity measurement (greater CV risk indicator)
Threshold: >40 inches (men) or >35 inches (women) = elevated risk
- 3
Comorbidity screening
BP, fasting glucose/A1C, lipid panel, sleep apnea symptoms, NAFLD evaluation
Threshold: Any comorbidity lowers threshold for medication (BMI ≥27)
- 4
Lifestyle intervention attempt
Document 3-6 months of structured diet + exercise (often required for insurance PA)
Threshold: <5% body weight reduction = insufficient
- 5
Pharmacotherapy evaluation
GLP-1, phentermine/topiramate, naltrexone/bupropion based on patient profile
Threshold: BMI ≥30 OR ≥27 with comorbidity = FDA-eligible
Source: AACE/ACE Comprehensive Clinical Practice Guidelines on Obesity (2016, updated)
Treatment decision criteria
When does a GLP-1 fit Obesity?
Criteria prescribers commonly weigh. Treatment decisions are your prescriber's — these are the factors that inform that decision.
Consider GLP-1 if…
- BMI ≥30, or BMI ≥27 with weight-related comorbidity (T2D, hypertension, dyslipidemia, OSA)
- Lifestyle intervention attempted ≥3-6 months without sufficient result
- Concurrent T2D — GLP-1 addresses both indications
- Established cardiovascular disease + obesity — Wegovy 2024 CVD indication
- Adolescents 12-17 (Wegovy and Saxenda only approved GLP-1s for this age)
Try alternatives first if…
- BMI 25-26.9 without comorbidity — lifestyle intervention only
- Active eating disorder (bulimia, binge eating disorder) — address first
- Pregnancy or planned within 2 months
- Personal/family history of medullary thyroid cancer or MEN 2
- Patient strongly prefers non-pharmacologic approach
First-line alternatives for Obesity
- Lifestyle intervention
- Always foundational — diet + exercise + behavioral support
- Bariatric surgery
- For BMI ≥40 or ≥35 with comorbidity; most effective long-term loss
- Phentermine + topiramate (Qsymia)
- Older anti-obesity med; lower cost option
- Naltrexone + bupropion (Contrave)
- Combination med targeting reward + appetite
Authoritative sources on Obesity
- Overweight & obesity — NIH — NIDDK
- Adult obesity facts — CDC